הכנסות החברה ImmuCell Corp (ICCC)

ImmuCell Corporation (ICCC) dominates the veterinary segment thanks to its unique FirstDefense antibodies, as confirmed by the company's revenue chart. The value of 0.03 indicates the level of this metric. Stable cash flow from livestock protection fully covers operating expenses. However, seasonal demand fluctuations and the risk of drug inefficiency during new epidemics create certain threats to quarterly profits.

To build a resilient portfolio, I prioritize assets with transparent cash flow. This metric captures the daily liquidity inflow from product sales, eliminating the time lags associated with quarterly reporting. For ImmuCell Corporation (ICCC), which dominates a niche veterinary segment, this is a critical marker for maintaining its market monopoly. Analyzing the company's gross sales volume on GURU.Markets allows for the timely detection of revenue erosion and prevents purchasing the asset at its peak.